Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2020-08-10 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Morepen Laboratories Ltd has informed BSE regarding loss of share Certificates of the Company
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (National Stock Exchange of India Ltd. and BSE Limited) regarding the loss of share certificates by a shareholder and the request for issuance of duplicate share certificates. It references Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The content is an announcement of an event related to share certificates, specifically the loss and replacement request, rather than a financial report, management update, or other regulatory filing. It does not contain financial data, management discussion, or voting results. It is not a report publication announcement or certification. The document fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about share certificate loss and related procedural information, which does not fit into more specific categories like share issue, director dealings, or capital updates.
2020-08-10 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure addressed to stock exchanges (NSE and BSE) regarding Related Party Transactions for the half year ended March 31, 2020. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 23(9). The content includes detailed related party transaction data and names of key management personnel and related parties. The document is not a full financial report but a regulatory disclosure of related party transactions, which is a common regulatory filing under SEBI rules. It is not an Annual Report, Interim Report, Earnings Release, or Management Discussion and Analysis. It is also not a report publication announcement or certification. Given the nature and regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2020-07-10 English
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements)(Amendments) Regulations, 2018, in connection to publication of the Standalone and Consolidated ....
Regulatory Filings Classification · 95% confidence The document is a disclosure of Related Party Transactions for the half year ended March 31, 2020, pursuant to SEBI regulations. It references the half-year period and contains detailed related party transaction data. It is not a full financial report but a regulatory disclosure related to financial results. The document is about related party transactions disclosure, which is typically part of regulatory filings under listing obligations. It is not an Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement of related party transactions as required by SEBI. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, indicating it is a full disclosure rather than a brief announcement or certification.
2020-07-10 English
Defaults on Payment of Interest/Principal
Regulatory Filings Classification · 95% confidence The document is a quarterly disclosure regarding the status of defaults on payment of interest/repayment of principal amount on loans and unlisted debt securities, pursuant to a SEBI circular dated November 21, 2019. It provides specific financial data as of June 30, 2020, including outstanding amounts and defaults. The document is relatively short (2350 characters) and is a regulatory compliance disclosure rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory filing to comply with SEBI requirements about debt default status disclosures. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-07-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an investors and analyst conference call discussing the Q4 FY 2019-2020 financial results of Morepen Laboratories Limited. It includes detailed commentary from the Chairman and CFO about the company's performance, challenges due to COVID-19, and financial figures for the quarter and year. The presence of a moderator, analyst questions, and management responses confirms this is a full call transcript. The document length (15,000 characters) and detailed content further support this classification. Therefore, the document fits the category of a Call Transcript (CT).
2020-07-03 English
Please find attached transcript of Investors and Analyst Conference Call organised on Monday, 29th June, 2020 at 12.00 Noon (IST) subsequent to declaration of Audited Financial Results ....
Call Transcript Classification · 100% confidence The document is a transcript of an investors and analyst conference call discussing the Q4 FY 2019-2020 financial results of Morepen Laboratories Limited. It includes detailed management commentary on business operations, financial performance, and the impact of COVID-19 on the quarter's results. The presence of a moderator, analyst questions, and management responses confirms it is a full call transcript. The document length (15,000 characters) and content depth indicate it is not a brief announcement or summary but a full transcript. Therefore, the appropriate classification is Call Transcript (CT).
2020-07-03 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.